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Clostridium difficile infection in patients with inflammatory bowel disease 
 Saidel-Odes, L et al., Annals of Gastroenterology, North America, November 24, 2011 
 http://www.annalsgastro.gr/index.php/annalsgastro/article/view/1010/739 
 This review focuses on the epidemiology, pertinent clinical aspects, standard and newer diagnostic 
methods, established and novel therapies and prevention of infection.  Emphasis is placed on clinical awareness, 
rapid detection and appropriate therapy. 
Rheumatological manifestations in inflammatory bowel disease 
 Voulgari, P, Annals of Gastroenterology, North America, July 24, 2011 
 http://www. Annalsgastro.gr/index.php/annalsgastro/article/view/915/720 
 Rheumatologic manifestations of inflammatory bowel disease are frequent and include peripheral 
arthritis, axial involvement, peripheral enthesitis, secondary osteoporosis and hypertrophic osteopathy; septic 
arthritis may also be a complication.  This article discusses diagnositic and treatment modalities as well as 
potential adverse effects of the therapeutic agents. 
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets 
 Bin Gao, Ramon Bataller, Gastroenterology, Vol 141, Issue 5, November, 2011, pages 1572-1585 
 http://www.gastrojournal.org/article/S0016-5085(11)01228-5/abstract 
 Hepatic cirrhosis is the 12th leading cause of death in the U.S. and 48% of cases are alcohol related. This 
article reviews new data on the pathogenesis of alcoholic liver disease and identifies some promising therapeutic 
targets. 
AGA technical review on the evaluation of liver chemistry tests 
 Green, RM and S Flamm, Gastroenterology, Vol 123, Issue 4, October 2002, pages 1367-1384 
 http://www.gastrojournal.org/article/S0016-5085(02)00241-X/abstract 
 Abnormal liver chemistries occur in 1-4% of asymptomatic patients.  There interpretation must be in 
context with the patients history, risk factors, physical findings and other lab data. 
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The AHRQ commissioned a systemic review of C diff.  Bottom line<.vancomycin ($1300) is probably not better 
than metronidazole ($20); also, fidaxomicin ($3400) appears to reduce relapse vs vancomycin for non-NAP1 
strains. 
 Drekonja, DM et al., Comparative effectiveness of Clostridium difficile treatments.  A systemic review.  
Annals Intern Med 2011; 155:839-847 
http://www.annals.org/content/155/12/839.full.pdf+html 
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